CINCINNATI, March 17 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced Dr. Ross Horsburgh, Vice President, Asia/Pacific will address the World Pharma Trials Asia 2010 conference being held March 17-18, 2010 at the Raffles City Convention Centre in Singapore. Dr. Horsburgh's presentation, "Accelerating Oncology Clinical Development in Asia," is scheduled for March 18 at 2 p.m. local time. World Pharma Trials Asia brings together pharmaceutical companies, biotechnology companies and CROs to explore outsourcing opportunities in Asia.
Dr. Horsburgh's presentation will explore key opportunities and challenges in oncology development in the region, discuss the benefits of including Asian countries in global development plans for oncology, define key success factors for conducting these trials in Asia and discuss best practices in selecting the optimal sites for exploratory oncology trials.
Following the conference, Dr. Horsburgh's presentation will be posted to the Kendle Web site at http://www.kendle.com/RW_media_show.php?cid=6.
Dr. Horsburgh is a trained medical physician with more than 20 years of experience in the CRO and pharmaceutical industries. He is responsible for the strategic oversight of all of Kendle's operations throughout the Asia/Pacific region, which includes offices in Beijing, Hong Kong and Shanghai, China; Ahmedabad and New Delhi, India; Kuala Lumpur, Malaysia; Bangkok, Thailand; Manila, Philippines; Sydney and Melbourne, Australia and Singapore.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.
SOURCE Kendle International Inc.Back to top
|SOURCE Kendle International Inc.|
Copyright©2010 PR Newswire.
All rights reserved